These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16434453)

  • 1. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial.
    Nielsen VE; Bonnema SJ; Hegedüs L
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1317-22. PubMed ID: 16434453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 0.9 mg recombinant human thyrotropin on thyroid size and function in normal subjects: a randomized, double-blind, cross-over trial.
    Nielsen VE; Bonnema SJ; Hegedüs L
    J Clin Endocrinol Metab; 2004 May; 89(5):2242-7. PubMed ID: 15126548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter.
    Nieuwlaat WA; Huysmans DA; van den Bosch HC; Sweep CG; Ross HA; Corstens FH; Hermus AR
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3121-9. PubMed ID: 12843153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter.
    Huysmans DA; Nieuwlaat WA; Erdtsieck RJ; Schellekens AP; Bus JW; Bravenboer B; Hermus AR
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3592-6. PubMed ID: 11061507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single, very low dose (0.03 mg) of recombinant human thyrotropin (rhTSH) effectively increases radioiodine uptake in the I-131 treatment of large nontoxic multinodular goiter.
    Mojsak MN; Abdelrazek S; Szumowski P; Rogowski F; Sykała M; Kostecki J; Kociura-Sawicka A; Jurgilewicz D; Myśliwiec J
    Nucl Med Rev Cent East Eur; 2016; 19(1):3-11. PubMed ID: 26841373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters.
    Nieuwlaat WA; Hermus AR; Sivro-Prndelj F; Corstens FH; Huysmans DA
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5330-6. PubMed ID: 11701700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial.
    Bonnema SJ; Nielsen VE; Boel-Jørgensen H; Grupe P; Andersen PB; Bastholt L; Hegedüs L
    J Clin Endocrinol Metab; 2007 Sep; 92(9):3424-8. PubMed ID: 17566091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter.
    Fast S; Nielsen VE; Grupe P; Boel-Jørgensen H; Bastholt L; Andersen PB; Bonnema SJ; Hegedüs L
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2653-60. PubMed ID: 22577172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial.
    Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Grupe P; Hegedüs L
    Arch Intern Med; 2006 Jul; 166(14):1476-82. PubMed ID: 16864757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH.
    Fast S; Nielsen VE; Bonnema SJ; Hegedüs L
    Clin Endocrinol (Oxf); 2010 Mar; 72(3):411-6. PubMed ID: 19508679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy.
    Fast S; Hegedüs L; Grupe P; Nielsen VE; Bluhme C; Bastholt L; Bonnema SJ
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3719-25. PubMed ID: 20519346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter.
    Giusti M; Cappi C; Santaniello B; Ceresola E; Augeri C; Lagasio C; Minuto F
    Minerva Endocrinol; 2006 Sep; 31(3):191-209. PubMed ID: 17213787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters.
    Braverman L; Kloos RT; Law B; Kipnes M; Dionne M; Magner J
    Endocr Pract; 2008 Oct; 14(7):832-9. PubMed ID: 18996810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of side effects after recombinant human thyrotropin-stimulated radioiodine treatment with 30 mCi in patients with multinodular goiter and subclinical/clinical hyperthyroidism.
    Romão R; Rubio IG; Tomimori EK; Camargo RY; Knobel M; Medeiros-Neto G
    Thyroid; 2009 Sep; 19(9):945-51. PubMed ID: 19678745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial.
    Nielsen VE; Bonnema SJ; Boel-Jørgensen H; Veje A; Hegedüs L
    J Clin Endocrinol Metab; 2005 Jan; 90(1):79-83. PubMed ID: 15494456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
    Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
    Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study.
    Fast S; Nielsen VE; Grupe P; Bonnema SJ; Hegedüs L
    J Nucl Med; 2009 May; 50(5):732-7. PubMed ID: 19403877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone.
    Nieuwlaat WA; Hermus AR; Ross HA; Buijs WC; Edelbroek MA; Bus JW; Corstens FH; Huysmans DA
    J Nucl Med; 2004 Apr; 45(4):626-33. PubMed ID: 15073259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers.
    Pena S; Arum S; Cross M; Magnani B; Pearce EN; Oates ME; Braverman LE
    J Clin Endocrinol Metab; 2006 Feb; 91(2):506-10. PubMed ID: 16317054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose recombinant human thyrotropin-aided radioiodine treatment of large, multinodular goiters in elderly patients.
    Cohen O; Ilany J; Hoffman C; Olchovsky D; Dabhi S; Karasik A; Goshen E; Rotenberg G; Zwas ST
    Eur J Endocrinol; 2006 Feb; 154(2):243-52. PubMed ID: 16452537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.